Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1964 1
1965 1
1967 1
1968 2
1969 2
1970 3
1971 5
1972 4
1973 4
1974 6
1975 7
1976 2
1978 1
1979 1
1980 2
1981 3
1983 1
1984 2
1985 1
1986 2
1987 2
1988 1
1989 2
1990 5
1991 7
1992 6
1993 5
1994 6
1995 5
1996 7
1997 5
1998 7
1999 12
2000 6
2001 11
2002 5
2003 7
2004 7
2005 15
2006 19
2007 11
2008 5
2009 8
2010 9
2011 10
2012 7
2013 4
2014 3
2015 6
2016 7
2017 6
2018 6
2019 8
2020 5
2021 9
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
The MPL mutation.
Guglielmelli P, Calabresi L. Guglielmelli P, et al. Int Rev Cell Mol Biol. 2021;365:163-178. doi: 10.1016/bs.ircmb.2021.09.003. Epub 2021 Oct 2. Int Rev Cell Mol Biol. 2021. PMID: 34756243 Review.
JAK2 mutation drives all the three major entities of MPN (Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis) through the constitutive activation of TPOR, erythropoietin (EPOR) and colony stimulating factor 3 receptor (CSF3R) signaling. ...
JAK2 mutation drives all the three major entities of MPN (Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis) thr …
Secondary erythrocytosis.
Babakhanlou R, Verstovsek S, Pemmaraju N, Rojas-Hernandez CM. Babakhanlou R, et al. Expert Rev Hematol. 2023 Apr;16(4):245-251. doi: 10.1080/17474086.2023.2192475. Epub 2023 Mar 23. Expert Rev Hematol. 2023. PMID: 36927204 Review.
Polycythemia Vera: Rapid Evidence Review.
Fox S, Griffin L, Robinson Harris D. Fox S, et al. Am Fam Physician. 2021 Jun 1;103(11):680-687. Am Fam Physician. 2021. PMID: 34060791 Free article. Review.
Polycythemia vera is one of three stem-cell-derived myeloid malignancies commonly known as myeloproliferative neoplasms. ...The World Health Organization's major diagnostic criteria include an elevated hemoglobin or hematocrit level, abnormal results on bone marrow biopsy, …
Polycythemia vera is one of three stem-cell-derived myeloid malignancies commonly known as myeloproliferative neoplasms. ...The World …
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W, Kralovics R. Vainchenker W, et al. Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Blood. 2017. PMID: 28028029 Free article. Review.
The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MPL mutants are restricted to MPL activation. This explains why JAK2V617F is associated …
The most frequent mutation, JAK2V617F, activates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-s …
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2022 Sep;183:106362. doi: 10.1016/j.phrs.2022.106362. Epub 2022 Jul 22. Pharmacol Res. 2022. PMID: 35878738 Review.
An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and about 50% of cases of myelofibrosis and essential thrombocythemia. ...Additionally, ruxolitinib is approved for the treatment of polycythemia vera while fedratinib, pacritinib, and …
An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and about 50% of cases of myelofibrosis and essentia …
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views.
Gangat N, Szuber N, Pardanani A, Tefferi A. Gangat N, et al. Leukemia. 2021 Aug;35(8):2166-2181. doi: 10.1038/s41375-021-01290-6. Epub 2021 May 21. Leukemia. 2021. PMID: 34021251 Free PMC article. Review.
JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses both hereditary and acquired conditions. ...Historically, management of non-PV erythrocytosis has been conflicted by unfounded concerns regarding thrombosis risk, stemming from limited phenotypic chara …
JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses both hereditary and acquired conditions. ...Historically, man …
Congenital erythrocytosis.
Mallik N, Das R, Malhotra P, Sharma P. Mallik N, et al. Eur J Haematol. 2021 Jul;107(1):29-37. doi: 10.1111/ejh.13632. Epub 2021 Apr 23. Eur J Haematol. 2021. PMID: 33840141 Review.
Erythrocytosis, or increased red cell mass, may be labeled as primary or secondary, depending on whether the molecular defect is intrinsic to the red blood cells/their precursors or extrinsic to them, the latter being typically associated with elevated erythropoietin (EPO) …
Erythrocytosis, or increased red cell mass, may be labeled as primary or secondary, depending on whether the molecular defect is intrinsic t …
Non-hematogenic activity of erythropoietin.
Stárka L, Dušková M. Stárka L, et al. Vnitr Lek. 2019 Summer;65(7-8):515-519. Vnitr Lek. 2019. PMID: 31487995 Review. English.
The cytokine erythropoietin is the main hemopoietic factor synthesized mainly by the kidney. ...This short review provides an insight into the nonhemopoietic role of erythropoietin and its mechanisms of action. For elimination of polycythaemia after erythr …
The cytokine erythropoietin is the main hemopoietic factor synthesized mainly by the kidney. ...This short review provides an insight …
Erythrocytosis Following Testosterone Therapy.
Ohlander SJ, Varghese B, Pastuszak AW. Ohlander SJ, et al. Sex Med Rev. 2018 Jan;6(1):77-85. doi: 10.1016/j.sxmr.2017.04.001. Epub 2017 May 16. Sex Med Rev. 2018. PMID: 28526632 Free PMC article. Review.
METHODS: A literature review was performed using PubMed for articles addressing TTh, erythrocytosis, and polycythemia. MAIN OUTCOME MEASURES: Mechanism, pharmacologic contribution, and risk of testosterone-induced erythrocytosis. ...Potential mechanisms explaining the rela …
METHODS: A literature review was performed using PubMed for articles addressing TTh, erythrocytosis, and polycythemia. MAIN OUTCOME M …
Congenital erythrocytosis.
McMullin MF. McMullin MF. Int J Lab Hematol. 2016 May;38 Suppl 1:59-65. doi: 10.1111/ijlh.12506. Epub 2016 May 9. Int J Lab Hematol. 2016. PMID: 27161533 Review.
The erythrocytosis can be primary where there is a defect in the erythroid compartment of secondary where increased erythropoietin production produced due to the defect leads to an erythrocytosis. ...Investigations for the cause include an erythropoietin level, oxyg …
The erythrocytosis can be primary where there is a defect in the erythroid compartment of secondary where increased erythropoietin pr …
294 results